Subscribe to EGRP Bulletins and News Flashes
You are welcome to invite others to subscribe to receive occasional Bulletins and News
Flashes from the Epidemiology and Genetics Research Program
(EGRP).
News
Flash, July 11, 2008
NIH Director Announces Enhancements to Peer Review
The National Institutes of Health (NIH) has announced critical changes to enhance and improve the NIH peer review system. An important component of the new plan is an increased commitment to investigator-initiated high-risk, high-impact research to prevent a slowdown of transformative research, despite difficult budgetary times.
The initiatives reflect NIH's response to thousands of comments, opinions, and criticisms received throughout the year. Taken together, these proposals bring to fruition the original charge to fund the best science, by the best scientists, with the least administrative burden.
Collaborative teams of participants worked to tackle challenges of the system and discover solutions. A comprehensive framework was created and implementation will be carried out over the next 18 months. The Implementation Plan Report consists of four main priorities and highlights include:
- Priority 1 – Engage the Best Reviewers: Increase flexibility of service, formally acknowledge reviewer efforts, further compensate time and effort, and enhance and standardize training
- Priority 2 – Improve Quality and Transparency of Reviews: Shorten and redesign applications to highlight impact and to allow alignment of the application, review and summary statement with five explicit review criteria, and modify the rating system
- Priority 3 – Ensure Balanced and Fair Reviews Across Scientific Fields and Career Stages
- Support a minimum number of early stage investigators and investigators new to NIH, and emphasize retrospective accomplishments of experienced investigators;
- Encourage and expand the Transformative Research Pathway;
- Create a new investigator-initiated Transformative R01 Award program funded within the NIH Roadmap with an intended commitment of a minimum of $250 million over five years;
- Continue the commitment of—and possibly expand the use of—the Pioneer, EUREKA, and New Innovator Awards. NIH will invest at least $750 million in these three programs over the next 5 years; and
- Reduce the burden of multiple rounds of resubmission for the same application, especially for highly meritorious applications.
- Priority 4 – Develop a Permanent Process for Continuous Review of Peer Review
For more information about enhancing peer review at NIH and to learn about the implementation plan, please visit http://enhancing-peer-review.nih.gov.
News
Flash, June 10, 2008
Reminder for NIH Study Section Members Planning to Submit Grant Applications with Budgets of $500,000 or More in Direct Costs in Any Given Year to Consult with Their Program Directors
In January 2008, the National Institutes of Health (NIH) announced a modified application submission, referral and review process for appointed NIH Study Section Members (see NIH Notice NOT-OD-08-026) planning to submit R01, R21, and R34 applications. Despite the alternate submission and review procedures for appointed study section members and ad hoc members (see NIH Notice NOT-08-027), the Awaiting Receipt of Application (ARA) process still applies when budget requests are likely to be submitted with direct costs >$500,000 in any given year. Applicants who are eligible for the alternate grant application submission procedures still must seek agreement from Institute/Center staff to accept assignment prior to the anticipated submission of any application (see NIH Notice, NOT-OD-02-004). Therefore, the Epidemiology and Genetics Research Program (EGRP) recommends that current and prospective grantees who serve on NIH Study Sections continue to contact EGRP Program Directors well in advance to discuss their submission plans and timelines for grant applications. Contact information for EGRP Program Directors.
Review of Key Web pages:
News
Flash, June 6, 2008
Funding Opportunity Announcements: Biomarkers of Infection-Associated Cancers
On behalf of the National Cancer Institute (NCI) and the National Institute of Dental and Craniofacial Research (NIDCR), NCI’s Epidemiology and Genetics Research Program (EGRP) announces two funding opportunity announcements (FOAs), that encourage the submission of Research Project Grant (R01) applications and Exploratory/Developmental Grant (R21) applications from institutions and organizations that propose to identify biomarkers for cancers where the etiology of the disease is attributed to infectious agents.
The objectives of these FOAs are to foster research to increase our knowledge of infectious agent-associated malignancies and identify those who are at increased risk of developing cancer among infected individuals and to detect early stage cancers in this population. The long-term goal of these FOAs is to encourage research that will increase our knowledge of infectious agent-associated malignancies and utilization of molecular profiles in early detection, risk assessment, and prevention of cancer. Listed below, but not limited to, are several programmatic areas in need of support for developing molecular signatures for infectious agent-associated cancers.
- Molecular profiles of normal, precancerous, and cancerous lesions following infection and of body fluids from infected individuals.
- Evaluation of these molecular profiles for use in gaining a better understanding of the role of infectious agents in cancer development and use in early detection, risk assessment, and prevention of cancer.
Awards issued under these FOAs are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.
R01 applicants requesting $500,000 or more in direct costs for any year (excluding consortium F&A costs) must carry out the following steps:
- Contact the appropriate NIH institute or center (IC) program staff member(s) at least 6 weeks before submitting the application, i.e., as plans are being developed for the study;
- Obtain agreement from the IC staff member that the IC will accept the application for consideration for award; and
- Include a cover letter with the application that identifies the staff member and IC that agreed to accept assignment of the application.
The total project period for R21 applications submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. The R21 is not renewable. Both FOAs expire May 8, 2011. Standard application submission and receipt dates apply.
The NCI cosponsors for these FOAs include the Division of Cancer Prevention and the Division of Cancer Biology. Please refer to the FOAs for the scientific contacts.
Access the NIH GUIDE FOR GRANTS AND CONTRACTS:
This News Flash from NCI’s Epidemiology and Genetics Research Program (EGRP) brings you news about:
- Comments on NIH’S Mandatory Public Access Policy for Publications Due By May 31; Apply for AIDS-Associated Supplements by June 15
- Requests for Supplements to Existing NCI Projects for Collaborations in AIDS-Associated Malignancies Due By June 15
News
Flash, April 29, 2008
Request for Information: Ideas for NIH Common Fund / Roadmap
Initiatives
The National Institutes of Health (NIH)'s Office of Portfolio Analysis
and Strategic Initiatives is seeking input from the scientific community,
health professionals, patient advocates, and the general public about
innovative and cross - cutting initiatives to be funded through the
NIH Common Fund. The Common Fund / Roadmap supports programs
that address fundamental knowledge gaps, develop transformative tools
and technologies, and/or foster innovative approaches to complex
problems. These programs are supported for a limited duration of
5-10 years. Collecting ideas is an initial step in the process
of identifying a new cohort of Common Fund / Roadmap programs for
Fiscal Year 2011. The NIH expects to spend $30 - 50 million per year
from within the currently projected budget for new 5-year initiatives.
Because NIH Institutes and Centers (ICs) regularly collaborate in
areas of shared interest, the IC Directors and the NIH Leadership
developed specific criteria for Common Fund / Roadmap programs. Primary
among these criteria is that the programs are expected to have exceptionally
high impact and to transform the way research is conducted. All
Common Fund / Roadmap programs are relevant to multiple diseases. All
ideas should meet the following criteria for new trans-NIH strategic
initiatives:
- Is the proposed initiative truly transforming - could it dramatically
affect how biomedical and/or behavioral research is conducted over
the next decade?
- Will the outcomes from the proposed initiatives
synergistically promote and advance the individual missions of
the Institutes and Centers to benefit health?
- Does the proposed
initiative require participation from NIH as a whole and/or does
it address an area (s) of science that does not clearly fall within
the mission of any one IC or OD program office?
- Is the proposed
initiative something that no other entity is likely or able to
do, and is there a public health benefit to having the results
of the research in the public domain?
Responses will be accepted through Friday, June 2, 2008. Please
limit your response to 1 page. To submit a response, please
e-mail roadmap_ideas@nih.gov
Access the NIH Guide for Grants and Contracts for details: NOT-RM-08-014.
News
Flash, April 22, 2008
Two Funding Opportunities Announced For Mitochondria Research In
Cancer Epidemiology, Detection, Diagnosis, And Prognosis
The National Cancer Institute (NCI) is sponsoring two Program Announcements
to stimulate the development and validation of novel mitochondrial
(mt) DNA biomarkers for understanding etiology, early detection,
diagnosis, prognosis, and risk assessment of cancer, and response
to preventive and ameliorative treatment. The PAs invite applications
using the Research Project Grant (R01) and the Exploratory/Developmental
Grants (R21) funding mechanisms. The Epidemiology and Genetics
Research Program (EGRP) is the initiator and a cosponsor of these
PAs.
Some of the specific research questions that may be addressed in
response to these PAs include, but are not limited to, the following:
- Are mitochondrial markers useful for identification of high risk
groups before clinical onset of disease?
- Are mitochondrial characteristics
or haplotypes associated with risk of developing cancer? If so,
can this help explain racial and ethnic differences in cancer risk?
- Are there modifiable factors or host factors that influence the
relationship between mtDNA characteristics and cancer risk?
- Are
mitochondria correlated with intermediate disease states in the
neoplastic pathway, such as precursor lesions?
- Are genetic and
mtDNA alterations (somatic mutations, deletions) correlated during
cancer development?
- Can the character of mtDNA anticipate the potential
aggressiveness of malignancy?
- How can mitochondrial markers be
utilized to predict disease progression and identify novel therapeutic
targets?
- Can we advance the technology for high-throughput analysis
and imaging of mitochondrial clustering?
- Are there unique mtDNA
mutations associated with specific types of cancers?
- How early can
mtDNA mutations be detected - can they be detected in pre-malignant
lesions such as PIN?
- Can a diagnostic assay based on mutations
in mtDNA alone or in combination with other markers be developed
for noninvasive detection and/or monitoring of cancer?
- Can nutrition
or chemopreventive agents ameliorate genetic effects of mitochondrial
activity induced mutational events?
Because the nature and scope of the proposed research will vary,
it is anticipated that the size and duration of each award will also
vary. The total project period for R21 applications submitted
in response to this funding opportunity announcement may not exceed
two years and direct costs are limited to $275,000 over the two-year
period, with no more than $200,000 in direct costs allowed in any
single year. Standard application submission and receipt dates apply.
Both PAs expire on May 8, 2011.
The contact for general questions about epidemiology is EGRP's Mukesh
Verma, Ph.D., Chief, Methods and Technologies Branch, and Acting
Chief, Host Susceptibility Factors Branch; e-mail: vermam@mail.nih.gov.
Also cosponsoring these PAs are NCI's Division of Cancer Prevention
(DCP), Division of Cancer Treatment and Diagnosis (DCTD), and the
Office of the Director (OD). Please refer to the PAs for the
scientific contacts.
Access the NIH Guide for Grants and Contracts for details: PA-08-143
(R01),
and PA-08-144
(R21)
News
Flash, April 18, 2008
FAQs Available About Administrative Supplements for Gene
Identification Efforts
Last month, the Epidemiology and Genetics Research Program
(EGRP) announced the availability of administrative supplements
for NIH-funded genetic association studies aimed at identifying
genetic factors involved in complex trait etiology. A set of Frequently
Asked Questions and Answers for applicants is now available.
Requests for supplements are due by May 1, 2008.
All current NIH awardees of
R01, P01, and P50 grants, and U01, U19, and U54 cooperative agreements
are eligible provided specific conditions are met. This opportunity
is part of the NIH-wide Genes,
Environment, and Health Initiative (GEI), in which
all NIH Institutes and Centers participate.
The supplements are to provide support for replication studies
(with or without fine-mapping) of genetic regions putatively associated
with the studied complex trait(s) (primarily those identified by
genome-wide association studies (GWAS)) in order to maximize the
productivity of NIH-funded GWAS.
Priority funding will be given
to studies with one of more of the following characteristics: synergy
with NIH’s Gene Environment
Association Studies, breadth of available phenotypic and exposure
measures for study participants, and plans for sharing data with
the research community. Studies should focus on replication in
the original discovery population if little replication information
is available to date. If the original “hit” has been
sufficiently replicated, studies should focus on populations not
included in the initial GWAS or subsequent replication studies,
such as groups with different environmental exposures.
Budget
requests must not exceed $400,000 in total costs for funding not
to exceed 12 months. Please note that the NIH Center for Scientific
Review (CSR) is not involved in receipt and processing of these
requests. NCI's EGRP will receive these administrative supplement
requests. See
instructions.
Contact: Elizabeth Gillanders, Ph.D., Program Director, Host
Susceptibility Factors Branch, EGRP; e-mail: lgilland@mail.nih.gov
News
Flash, April 10, 2008
NIH Seeks Info on Pharmacogenomics by April 20th
We thought you might be interested in an opportunity to
respond to a Request for Information (RFI) on challenges and barriers
to pharmacogenomics research. The request is from the Trans-NIH Pharmacogenomics
Working Group. The RFI is in the form of an on-line series of questions
intended to reveal gaps and highlight opportunities in pharmacogenomics,
and to aid in identifying specific, achievable goals that will advance
and transform the field overall. NIH wants to consider research needs
from discovery-based efforts to validation and applied research,
in order to accelerate the translation of pharmacogenomics discoveries
into the clinical realm.
NIH is interested in responses that suggest
transformative ideas and approaches. The best ideas will have great
potential to dramatically affect how biomedical research is conducted
over the next decade, yet will be concrete and achievable tasks.
Moreover, NIH wants to leverage existing research mechanisms and
resources. Ideas for enabling research efforts of interest would
be those challenges to pharmacogenomics that: (1) are activities
that no other entity is likely to be able to successfully conduct,
(2) will generate knowledge that can be made publicly accessible,
and (3) are of clear benefit to public health.
Responses must be
submitted electronically at http://www.nigms.nih.gov/Initiatives/NIH-RFI and
will be accepted through April 30, 2008.
Contact: Rochelle M. Long,
Ph.D., Chief, Pharmacology & Physiological Sciences Branch; Pharmacology,
Physiology, & Biological Chemistry Division, National Institute
of General Medical Sciences (NIGMS), e-mail: Rochelle.long@nih.gov.
Access the NIH Guide for Grants and Contracts for details:
NOT-GM-08-125.
News
Flash, April 3, 2008
Policy of the National Cancer Institute for Allowable Requested
Budget Levels of Competing Continuation (Type 2) R01, U01 and P01
Applications
The Epidemiology and Genetics Research Program (EGRP)
reminds current and prospective grantees that NCI restricts all competing
continuation (Type 2) R01, U01 and P01 applications to a 20% increase
over the last funding period. In cases where the last non-competing
year may be substantially lower than previous years, applicants may
cite the average yearly direct cost for the previous funding period
as the base for the policy cap on the Type 2 applications. Type 2
applications that are within the pay line or selected for funding
by exception that do not conform to the cap will be subject to a
reduction in the total budget to align it with the NCI Type 2 policy,
in addition to the current NCI programmatic reductions and applicable
Study Section/Integrative Review Group recommended reductions.
Answers
to frequently asked questions are available for R01s
and U01s. For questions about P01s, contact an EGRP
Program Director.
Access the NIH Guide for Grants and Contracts for details:
News
Flash, March 14, 2008
Funding Opportunity Announcement: Rare Diseases Clinical Research
Consortia (RDCRC) for the Rare Diseases Clinical Research Network
On behalf of the NIH Office of Rare Diseases (ORD), NCI's Epidemiology
and Genetics Research Program (EGRP) announces a Request for Applications
(RFA) for new and renewal cooperative agreement applications (U54)
for Rare Diseases Clinical Research Consortia (RDCRC). Proposals
are sought for RDCRCs that individually focus on a subset of related
rare diseases.
Each RDCRC will consist of a consortium of clinical investigators,
institutions, and relevant organizations, including patient support
organizations, focused on a subgroup of rare diseases. Support is
provided for 1) collaborative clinical research in rare diseases,
including longitudinal studies of individuals with rare diseases,
clinical studies and/or phase I, II, and II/III trials; 2) training
of clinical investigators in rare diseases research; 3) pilot and
demonstration projects 4) a test bed for distributed clinical data
management that incorporates novel approaches and technologies for
data management, data mining, and data sharing across rare diseases,
data types, and platforms; and 5) access to information related to
rare diseases for basic and clinical researchers, academic and practicing
physicians, patients, and the lay public.
Required components of a RDCRC application include:
- A minimum of two clinical research projects (at least one of
them must be a longitudinal study);
- A training (career development)
component;
- At least one pilot/demonstration project;
- A Web site for educational and research resources in rare
diseases;
- Collaboration with patient support organization(s); and
- An administrative unit
The NIH ORD and participating NIH Institutes and Centers intend
to commit approximately $8.75 million in Fiscal Year 2009 to fund
up to seven new and/or renewal grant applications for RDCRCs. If
additional funds become available, approximately ten consortia
may be funded. An applicant must request a project period for five
years. In general, budget requests should be limited to $1.25 million
in total cost.
Letters of Intent are due July 20, and applications are due by
August 20, 2008.
Contact: Elizabeth Read-Connole, Ph.D., NCI Representative to the
Office of Rare Diseases Committee; email bconnole@mail.nih.gov.
Access the NIH Guide for Grants and Contracts for details:
RFA-OD-08-001.
News
Flash, March 6, 2008
Administrative Supplements for Gene Identification Efforts: Replication and Fine-Mapping Studies: The Genes, Environment, and Health Initiative (GEI)
On behalf of the NIH-wide Genes, Environment, and Health Initiative (GEI), NCI’s Epidemiology and Genetics Research Program (EGRP) announces the availability of administrative supplements for NIH-funded genetic association studies aimed at identifying genetic factors involved in complex trait etiology. The purpose of this funding opportunity is to provide support for replication studies (with or without fine-mapping) of genetic regions putatively associated with the studied complex trait(s) (primarily those identified by genome-wide association studies (GWAS)) in order to maximize the productivity of NIH-funded GWAS. This opportunity is open to all current NIH awardees of R01, P01, and P50 grants, and U01, U19, and U54 cooperative agreements, provided specific conditions are met. Learn more about the GEI initiative.
Priority funding will be given to studies with one of more of the following characteristics: synergy with NIH’s Gene Environment Association Studies, breadth of available phenotypic and exposure measures for study participants and plans for sharing data with the research community. Studies should focus on replication in the original discovery population if little replication information is available to date. If the original “hit” has been sufficiently replicated, studies should focus on populations not included in the initial GWAS or subsequent replication studies, such as groups with different environmental exposures.
Requests are due by May 1, 2008. Budget requests must not exceed $400,000 in total costs for funding not to exceed 12 months. Please note that the NIH Center for Scientific Review (CSR) is not involved in receipt and processing of these requests. NCI's EGRP will receive these administrative supplement requests. Detailed application instructions.
Contact: Elizabeth Gillanders, Ph.D., Program Director, Host Susceptibility Factors Branch; e-mail: lgilland@mail.nih.gov.
Access the NIH Guide for Grants and Contracts for details: NOT-CA-08-011: Administrative Supplements for Gene Identification Efforts: Replication and Fine-Mapping Studies for the Genes, Environment, and Health Initiative (GEI)
News
Flash, February 25, 2008
Request for Applications Announced for Comparative Systems Genetics of Cancer
The National Cancer Institute (NCI), in collaboration with the National Institute of Environmental Health Sciences (NIEHS), has announced a Request for Applications (RFA) for grant applications for research projects (R01s) focused on the development and application of comparative (cross-species) systems genetics approaches to address key cancer-relevant problems. Proposals are sought for research projects that will use these approaches to enhance the understanding of the mechanisms that underlie (1) human cancer susceptibility and (2) heterogeneity of human tumors.
To meet these two goals, proposed projects are expected to involve appropriate interdisciplinary collaborations providing expertise in such areas as human genetics, statistical genetics, model organism genetics, systems biology, mathematical or computational modeling of biological processes, and computer sciences. All projects are required to propose use of two species, one of which must be human, and projects must adhere to the cancer Biomedical Informatics Grid (caBIG™) standards.
Examples of research topics for investigation may include, but are not limited to, the following areas:
- Characterize the genetic networks that produce the variable manifestations of a specific human cancer;
- Integrate available genome-wide association studies (GWAS) and model organism genetic data into a testable, system-level model of a specific human cancer;
- Determine mechanisms of genetic perturbations by environmental factors in a specific human cancer
- Evaluate data models that incorporate genetic and environmental factors to refine phenotypes that enable subcategorization of a specific human cancer;
- Develop and test data models that account for the interaction of genotype and environment in determining phenotypic responses to the environment that may be related to human cancer;
- Determine the influence of genetic variation on systems-level responses to environmental factors relevant to cancer in humans;
- Understand mechanisms of perturbations of pathways implicated in environmentally induced diseases;
- Develop and test models to predict toxicological responses in highly connected genes and disease pathways that are evolutionarily conserved; and
- Understand susceptibility to toxic compounds in model organisms and humans.
NCI intends to commit about $3 million per year for up to 5 years to fund four to six individual multidisciplinary research programs. The NCI sponsors are EGRP, which is part of the Division of Cancer Control and Population Sciences (DCCPS), and the Division of Cancer Biology (DCB).
Programmatic inquiries may be directed to: Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch (MTB), EGRP, NCI, e-mail: vermam@mail.nih.gov; Cheryl Marks, Ph.D., Associate Director, DCB, NCI, e-mail: marksc@mail.nih.gov; and Kimberly McAllister, Ph.D., Program Administrator, NIEHS, e-mail: mcallis2@niehs.nih.gov.
Read the complete RFA, RFA-CA-08-017, in the NIH Guide for Grants and Contracts.
News
Flash, February 11, 2008
NCI Epidemiology and Genetics Research Program Seeks Program Directors
The Epidemiology and Genetics Research Program (EGRP), Division
of Cancer Control and Population Sciences (DCCPS), National Cancer
Institute (NCI), has two openings for cancer epidemiologists. Program
Directors develop, coordinate, and manage a national and international
extramural research portfolio of grants in cancer epidemiology and
identify research opportunities that lead to new scientific initiatives.
The positions offer wonderful opportunities for those who are interested
in helping to shape the direction of cutting-edge cancer epidemiology
research. Successful candidates will have significant leadership
and collaborative opportunities with NCI scientists on important
scientific initiatives related to cancer epidemiology, including
but not limited to cancer control, cancer research consortia, cancer
genetics, health disparities, etc.
NCI is part of the National Institutes of Health (NIH), U.S. Department
of Health and Human Services (DHHS). EGRP is the largest funder of
etiologic cancer epidemiology grants nationally and worldwide. It
supports epidemiologic research in four areas: methods and technologies
for epidemiologic studies; modifiable risk factors (e.g., energy
balance and environmental and infectious agent exposures); host susceptibility
risk factors (e.g., social, genetic, and race/ethnicity factors);
and clinical and translational research (e.g., risk factors for second
primary cancers and the effects of prophylactic approaches). EGRP's
offices are located in Rockville, MD, a suburb of Washington, DC.
Further information about EGRP.
Qualifications: U.S. citizenship is a requirement. A doctoral degree
and formal training in epidemiology are required. Candidates must
have: knowledge of epidemiologic research methodologies necessary
to develop epidemiologic research studies; ability to administer,
conduct, and evaluate multidisciplinary epidemiologic research; skill
in oral communication as it pertains to a research area; and skill
in written communication as it pertains to a research program area.
Salary range: The positions are available at the GS 13/14 level,
for which the 2008 pay range is $82,961-$127,442 per year. Relocation
expenses may be paid.
The position is advertised on the USAJOBS
Web site as Health Scientist
Administrator (Epidemiologist). To be considered for this position,
candidates must formally apply through
the Web site.
The deadline for applications is March 5, 2008. Access the complete
announcement and application materials by inserting in the keyword
search box the following announcement number: NCI-08-241044-DE. After
beginning the online application process through the above announcement
number, Federal government status candidates will be guided to apply
under announcement number NCI-08-241044-MP.
Inquiries about this position may be directed to the Personnel Officer
named in the announcements: Ms. Anne Solomon, tel.: 301-496-8737;
fax: 301- 496 6168; e-mail: ncihrmcbapps@mail.nih.gov .
News
Flash, February 7, 2008
Supplements Offered for Dissemination of Cancer-Related Surveillance
Research
Our Division of Cancer Control and Population Sciences (DCCPS) is
sponsoring administrative supplements for dissemination of cancer-related
surveillance research. Current National Cancer Institute (NCI) awardees
of R01, P01, P50, U01, and U19 grants pertaining to cancer control
are eligible to apply provided the conditions listed below are met.
The application deadline is April 1, 2008.
The conditions are:
- The topic area of the original cancer control award must be related
to the focus of the surveillance research/surveillance data analysis
that is being proposed in the supplement request (for example,
if the parent grant focuses on physical activity, the supplement
should focus on the dissemination of surveillance data on physical
activity);
- The proposed surveillance dissemination effort must
clearly be beyond the scope of the “parent” award;
- The “parent” award must remain active during the entire funding period of this supplement; and
- The Principal Investigator (PI) for the supplement must be the
PI of the “parent” award.
Diverse aspects of cancer control might be appropriate for dissemination
efforts under these supplements (for example, cancer risk factors,
screening, cancer rates, treatment, and outcomes). Specific areas
include, but are not limited to:
- tobacco use;
- diet and physical activity patterns;
- sun exposure and ultraviolet radiation exposure;
- use of chemopreventive agents;
- use of genetic testing for cancer susceptibility;
- use of screening for breast, cervix, and colorectal cancers;
- cancer rates, morbidity, and mortality;
- cancer treatment and patterns of care; and
- cancer outcomes.
The goals of these supplements are to:
- Fund innovative dissemination of surveillance research results
to increase application of these results in policy, practice, and
communities across the cancer continuum;
- Encourage surveillance researchers to develop and test ways
to expand use of their data;
- Encourage researchers and program planners in other areas, such
as communication and intervention research, to consider ways to
use surveillance data in their research or programs; and
- Encourage transdisciplinary collaborations between researchers
in surveillance and other areas, such as communications and interventions.
NCI intends to commit about $200,000 in FY 2008 to fund about
two (2) administrative supplements in response to this initiative.
Budget requests must not exceed $100,000 in total costs for a funding
period not to exceed 12 months.
Access the NIH Guide for Grants and Contracts Notice (NOT-CA-08-008),
for Frequently Asked Questions, and detailed instructions on applying.
Requests for these administrative supplements must be submitted
to DCCPS by the April 1 due date. Note that the National Institutes
of Health’s
(NIH) Center for Scientific Review (CSR) is not involved in receipt
and processing of these requests.
News
Flash, February 5, 2008
NIH Announces Manufacturing Assistance Program (MAP) for Its Phase
II SBIR Awardees
The National Institutes of Health (NIH) announced
the availability of a Manufacturing Assistance Program (MAP) for
its Small Business Innovation Research (SBIR) Phase II awardees from
2003 to the present. We want to be sure that you are aware of this
opportunity. This new program is designed to help SBIR awardees identify,
address, and develop a strategy to overcome the manufacturing issues
related to the commercialization of their SBIR-developed products.
(NOTE: This program is not available to Small Business Technology
Transfer [STTR] awardees.) Applications are due February 14, 2008;
however, if you’re interested, act quickly as the first 30
applications received will be considered for the 25 slots that are
available.
Review the NIH Guide Notice NOT-OD-08-025 (released
Dec. 28, 2007) for the program’s full description and the application
form.
- EGRP Seeks Two Branch Chiefs and Additional Program Directors
- EGRP Staff News
- Virginia (Ginny) Hartmuller, Ph.D., R.D., Retires
- Elizabeth (Liz) Gillanders, Ph.D., Joins as
Program Director
- Michael Donovan, Ph.D., Does Rotation as Presidential
Management Fellow
- Damali Martin, Ph.D., M.P.H., Joins as Cancer Prevention
Fellow
- EGRP Provides Assistance To Develop Cancer Epidemiology
Consortia
- EGRP Funding Opportunities
- Development, Application, and Evaluation of Prediction Models for
Cancer Risk and Prognosis PAs
- Small Grants Program for Cancer Epidemiology PAR
- Epigenetic Approaches in Cancer Epidemiology PAs
- Occupational Safety and Health Research PAs
- Pilot Studies in Pancreatic Cancer PAs
- Research on Malignancies in the Context of HIV/AIDS PAs
- Studies of Energy Balance and Cancer in Humans PAs
- Exfoliated Cells, Bioactive Food Components, and Cancer PAs
- Small Business Grants (SBIR: R43/44, STTR: R41/42)
- Other NIH and NCI Funding Opportunities
- NIH Director’s New Innovator Award Program
(DP2) RFA
- NIH Roadmap Initiative on Epigenetics RFAs
- NCI Innovative Molecular Analysis Technologies (IMAT)
Program RFAs
- Institutional Clinical and Translational
Science Award RFA
- Grantsmanship
- Step-by-Step Help on Preparing Progress Reports
and Final Reports With EGRP
- NIH Data Sharing Policy In Effect for Genome-Wide
Association Studies (GWAS)
- NIH Issues Revised Policy on Enhancing Public
Access to Archived Publications From NIH-Funded Research
- Grant Applications Must Tie to Funding Opportunity
Announcements
- Paper Notification of Notice of Awards Stops
- NIH Summarizes Policy on Late Grant Applications
- Standing NIH Study Section Members Offered Modified
Grant Application Submission, Referral, and Review
- NIH Issues New Application Forms: Relinquishing
Grant, Noncompeting Continuation Progress Report
- NIH Web Site Showcases Small Business Technologies
and Products for Potential Partners, Investors, and Licensees
- Meetings
- NIH Regional Seminars on Funding and Grants Administration
Set for San Antonio in March, Chicago in June
- NIH Small Business Grants Conference Set for Atlanta,
July 22-23, 2008
- EGRP-Supported Research Resources
- Long Island Geographic Information System (GIS)
Available for Breast Cancer, Other Disease Research
- Breast and Colon Cancer Family Registries (CFRs)
- Cancer Genetics Network (CGN)
EGRP Announces Appointments of Two New Branch Chiefs
NCI’s Epidemiology and Genetics Research Program (EGRP) has two new Branch Chiefs. Britt
Reid, D.D.S., Ph.D., has been named to head the Modifiable Risk Factors Branch (MRFB) and Mukesh
Verma, Ph.D., has been named to head the Methods and Technologies Branch (MTB). These appointments are part of last year’s
reorganization of EGRP which included changing from a two-branch to a four-branch
structure. Learn more about Drs. Reid and Verma and
these appointments.
Subscribe to EGRP Bulletins and News Flashes
You are welcome to invite others to subscribe to receive occasional Bulletins and News
Flashes from the Epidemiology and Genetics Research Program
(EGRP).
Other Sources of News:
